These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 12952496)

  • 1. Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans.
    Almeida L; Soares-da-Silva P
    Drugs R D; 2003; 4(5):269-84. PubMed ID: 12952496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans.
    Almeida L; Soares-da-Silva P
    J Clin Pharmacol; 2004 Aug; 44(8):906-18. PubMed ID: 15286095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of BIA 3-202, a novel COMT inhibitor, during first administration to humans.
    Almeida L; Soares-da-Silva P
    Drugs R D; 2003; 4(4):207-17. PubMed ID: 12848585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024.
    Ambrósio AF; Soares-Da-Silva P; Carvalho CM; Carvalho AP
    Neurochem Res; 2002 Feb; 27(1-2):121-30. PubMed ID: 11926264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative bioavailability, metabolism and tolerability of rectally administered oxcarbazepine suspension.
    Clemens PL; Cloyd JC; Kriel RL; Remmel RP
    Clin Drug Investig; 2007; 27(4):243-50. PubMed ID: 17358096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers.
    Perkins D; Butler J; Ong K; Nguyen TH; Cox S; Francis B; Mcintosh M; Lilley B
    Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):575-586. PubMed ID: 32409982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurotoxic/neuroprotective profile of carbamazepine, oxcarbazepine and two new putative antiepileptic drugs, BIA 2-093 and BIA 2-024.
    Ambrósio AF; Silva AP; Araújo I; Malva JO; Soares-da-Silva P; Carvalho AP; Carvalho CM
    Eur J Pharmacol; 2000 Oct; 406(2):191-201. PubMed ID: 11020481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of oral loading of oxcarbazepine suspension in selected patients with epilepsy.
    Kim DW; Gu N; Lee H; Jang IJ; Chu K; Yu KS; Cho JY; Yoon SH; Na HJ; Lee SK
    Int J Clin Pharmacol Ther; 2013 Oct; 51(10):780-6. PubMed ID: 23849326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
    Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P
    Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic profiles of BIA 3-202, a novel catechol-O-methyltransferase (COMT) inhibitor, during multiple-dose administration to healthy subjects.
    Almeida L; Soares-da-Silva P
    J Clin Pharmacol; 2003 Dec; 43(12):1350-60. PubMed ID: 14615471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers.
    Elger C; Bialer M; Falcão A; Vaz-da-Silva M; Nunes T; Almeida L; Soares-da-Silva P
    Epilepsia; 2013 Aug; 54(8):1453-61. PubMed ID: 23758485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, pharmacokinetics, and pharmacodynamics of CHF 3381, a novel N-methyl-D-aspartate antagonist, after single oral doses in healthy subjects.
    Tarral A; Dostert P; Guillevic Y; Fabbri L; Rondelli I; Mariotti F; Imbimbo BP
    J Clin Pharmacol; 2003 Aug; 43(8):901-11. PubMed ID: 12953347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures.
    Perucca E; Elger C; Halász P; Falcão A; Almeida L; Soares-da-Silva P
    Epilepsy Res; 2011 Sep; 96(1-2):132-9. PubMed ID: 21680153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurotoxicity induced by antiepileptic drugs in cultured hippocampal neurons: a comparative study between carbamazepine, oxcarbazepine, and two new putative antiepileptic drugs, BIA 2-024 and BIA 2-093.
    Araújo IM; Ambrósio AF; Leal EC; Verdasca MJ; Malva JO; Soares-da-Silva P; Carvalho AP; Carvalho CM
    Epilepsia; 2004 Dec; 45(12):1498-505. PubMed ID: 15571507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy.
    Rey E; Bulteau C; Motte J; Tran A; Sturm Y; D'Souza J; Markabi S; Pons G; Dulac O
    J Clin Pharmacol; 2004 Nov; 44(11):1290-300. PubMed ID: 15496647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa.
    Almeida L; Vaz-da-Silva M; Silveira P; Falcão A; Maia J; Loureiro A; Torrão L; Machado R; Wright L; Soares-da-Silva P
    Clin Neuropharmacol; 2004; 27(1):17-24. PubMed ID: 15090932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
    Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
    Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism of 10,11-dihydro-10-hydroxyimino-5H-dibenz/b, f/azepine-5-carboxamide, a potent anti-epileptic drug.
    Hainzl D; Loureiro AI; Parada A; Soares-da-silva P
    Xenobiotica; 2002 Feb; 32(2):131-40. PubMed ID: 11868969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers.
    Nunes T; Rocha JF; Falcão A; Almeida L; Soares-da-Silva P
    Epilepsia; 2013 Jan; 54(1):108-16. PubMed ID: 22812691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.